Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Maurizio Zangari

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following properties of Zangari, Maurizio

PropertyValue
overview Maurizio Zangari, M.D. is a Professor of Medicine with the Myeloma Institute for Research and Therapy at UAMS. Dr. Zangari trained as a fellow in Bone Marrow Transplant and Hematology at Mount Sinai Hospital in New York and a resident in Internal Medicine at Wykoff Heights Medical Center, also in New York. He earned is MD from the University of Padua in Italy. Dr. Zangari was previously at the Myeloma Center from 1998-2007, then left for the University of Utah from 2007-2013. He rejoined the Myeloma Center in 2013 and continues to be greatly involved with clinical trials and research. He is an internationally recognized expert in multiple myeloma with an extensive bibliography of peer-reviewed articles and invited presentations. Dr. Zangari is board certified in Hematology and Internal Medicine. He is a member of the American Society of Hematology.
research overview Hypercoagulability in Cancer Patients. The role of activated protein C in thrombotic manifestation of patients with multiple myeloma. Since the start at the University of Utah I have initiated retrospective and prospective studies of the protein C system function in patients with paraproteinemias and myeloproliferative disorder. I have also continued to test the effect of proteosome inhibition on platelet function. After establishing 5GTM1 C57BL/KaLwRij sub-strain in a pre-clinical model I have tested the function of a proteasome inhibitor through the PTH-PTHR axis. In the last 22 months I focused the research to confirm the hypothesis of the PTH essential role in anti-myeloma proteasome activity testing the effect of PTHR antibodies and the effects of parathyroidectomy. The C57 BLACK MOUSE MODEL will be measured in the presence of different proteasome inhibitors MLN 9708, carfilzomib and CEP 18770. I am the principal investigator in three open investigator-initiated trials (Phase I Exploratory Study of Panobinostat IV in Combination with Relapsed/Refractory Multiple Myeloma Patients; Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients; Bone Effect of Bortezomib in Patients with relapsed/refractory Multiple Myeloma), which focus on the bone anabolic activity of proteasome inhibition to determine the minimal proteosome inhibition associated with the anabolic bone effect in multiple myeloma and to evaluate the effect of proteasome inhibition in smoldering myeloma patients. A phase I study, a combination of two bone anabolic drugs panabinostat (a histone deacetylase inhibitor HDAC) and bortezomib in relapse/refractory multiple myeloma patients.

One or more keywords matched the following items that are connected to Zangari, Maurizio

Item TypeName
Academic Article Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Academic Article Infection--an underappreciated cause of bone pain in multiple myeloma.
Academic Article High heparanase activity in multiple myeloma is associated with elevated microvessel density.
Academic Article Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model.
Academic Article High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis.
Academic Article Monoclonal gammopathy of undetermined significance: a consensus statement.
Academic Article Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications.
Academic Article Response to bortezomib and activation of osteoblasts in multiple myeloma.
Academic Article Oral administration of analgesia and anxiolysis for pain associated with bone marrow biopsy.
Academic Article Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma.
Academic Article Complete response in myeloma extends survival without, but not with history of prior monoclonal gammopathy of undetermined significance or smouldering disease.
Academic Article A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients.
Academic Article Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.
Academic Article Impact of bortezomib on bone health in myeloma: a review of current evidence.
Academic Article The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo.
Academic Article Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.
Academic Article Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.
Academic Article Bone and paraproteinemias.
Concept Bone Diseases
Concept Bone Neoplasms
Concept Bone Development
Concept Bone Resorption
Concept Bone Diseases, Metabolic
Concept Bone Marrow
Concept Bone Marrow Cells
Concept Bone Density
Concept Bone and Bones
Concept Bone Marrow Transplantation
Concept Bone Remodeling
Concept Bone Density Conservation Agents
Academic Article Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors.
Academic Article Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.
Academic Article Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).
Academic Article The effects of proteasome inhibitors on bone remodeling in multiple myeloma.
Academic Article Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.
Academic Article Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease.
Academic Article Surgical thyroparathyroidectomy prevents progression of 5TGM1 murine multiple myeloma in vivo.
Academic Article The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.
Academic Article Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma.
Academic Article Visualizing collagen proteolysis by peptide hybridization: From 3D cell culture to in vivo imaging.
Academic Article FRAX is a robust predictor of baseline vertebral fractures in multiple myeloma patients.
Academic Article Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.
Academic Article Innate Biomineralization.
Academic Article Monitoring treatment response and disease progression in myeloma with circulating cell-free DNA.
Academic Article Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials.
Academic Article Bone remineralization of lytic lesions in multiple myeloma - The Arkansas experience.
Academic Article Persistent bone marrow minimal residual disease as a "high-risk" disease feature in multiple myeloma.
Academic Article Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma.
Academic Article Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma.
Academic Article CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation.
Academic Article Characterizing the role of the immune microenvironment in multiple myeloma progression at a single-cell level.
Academic Article Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy.
Academic Article EDNRA-Expressing Mesenchymal Cells Are Expanded in Myeloma Interstitial Bone Marrow and Associated with Disease Progression.
Academic Article Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma.

Search Criteria
  • Bone and Bones